ACIST enters StatSensor Creatinine Meter distributing agreement

ACIST Medical Systems, a Bracco Group company, has signed a distribution agreement with Nova Biomedical to distribute the StatSensor Creatinine Meter.

Under the agreement, ACIST and the Waltham, Mass.-based Nova will co-exclusively market and distribute the StatSensor Creatinine Meter for radiology and cardiology within North America initially, the two companies said.

The Eden Prairie, Minn.-based ACIST said it will continue to support customers who have previously purchased the StatSensor Creatinine Meter under the E-Z-Chem brand name from E-Z-EM, prior to its acquisition of E-Z-EM.

The StatSensor Creatinine device quickly measures a patients blood creatinine level and calculates their estimated glomerular filtration rate prior to contrast agent administration via a finger prick, allowing the clinician to assess patient renal function and eligibility for IV contrast administration thereby minimizing the potential for contrast-induced nephropathy, ACIST said.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.